Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

Blood

Volumn 117, Issue 24, 2011, Pages 6660-6668

  Lucas, Claire M ^a   Harris, Robert J ^a   Giannoudis, Athina ^a   Copland, Mhairi ^b   Slupsky, Joseph R ^a   Clark, Richard E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL 1 PROTEIN; BCR ABL PROTEIN; BIOLOGICAL MARKER; CANCEROUS INHIBITOR OF PHOSPHOPROTEIN PHOSPHATASE 2A; CD34 ANTIGEN; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN SET; SET BINDING PROTEIN 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MONONUCLEAR CELL; ONCOGENE C MYC; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 79959252521     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-304477     Document Type: Article

References (34)

1. Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22(10):1963-1966.
2. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358- 3363.
3. Lucas CM, Harris RJ, Giannoudis A, Knight K, Watmough SJ, Clark RE. BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2010;149(3):458-460.
4. Sattler M, Salgia R, Okuda K, et al. The protooncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3 kinase pathway. Oncogene. 1996;12(4):839-846.
5. Sánchez-Arévalo Lobo VJ, Aceves Luquero CI, Alvarez-Vallina L, et al. Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J. 2005;387(1):231-238. (Pubitemid 40524093)
6. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353(3):417-439. (Pubitemid 32158309)
7. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer. 2006;95(7):775-781. (Pubitemid 44500626)
8. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8(5):355-368. (Pubitemid 41579831)
9. Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009;28(14):1669-1681.
10. Cristobal I, Blanco FJ, Garcia-Orti L, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood. 2010;115(3):615-625.
11. Lucas CM, Harris RJ, Giannoudis A, Davies A, Clark RE. SET binding protein 1 expression does not predict clinical outcome in chronic myeloid leukemia [e-letter]. Blood. 2010. http://bloodjournal.hematologylibrary.org/ content/115/3/615.short/reply bloodjournal-el-59. Published April 1, 2010.
12. Junttila MR, Puustinen P, Niemela M, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007; 130(1):51-62. (Pubitemid 47039258)
13. Côme C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15(16):5092-5100.
14. Li W, Ge Z, Liu C, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14(12): 3722-3728.
15. Khanna A, Bockelman C, Hemmes A, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009; 101(11):793-805.
16. Kerosuo L, Fox H, Perälä N, et al. CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. Differentiation. 2010;80(1): 68-77.
17. Wang J, Li W, Li L, Yu X, Jia J. CIP2A is overexpressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol. 2011;33(3):290-298.
18. Coenen EA, Zwaan CM, Meyer C, et al. KIAA1524: a novel MLL translocation partner in acute myeloid leukemia. Leuk Res. 2011;35(1): 133-135.
19. Lucas CM, Harris RJ, Giannoudis A, et al. Chronic myeloid leukaemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib than e14a2 patients. Haematologica. 2009;94(10):1362-1367.
20. Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol. 2002;118(3):771-777. (Pubitemid 35007381)
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[delta][delta]CT method. Methods. 2001;25(4):402-408. (Pubitemid 34164012)
22. Hamilton A, Alhashimi F, Myssina S, Jorgensen HG, Holyoake TL. Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. Exp Hematol. 2009;37(3):395-401.
23. Wang J, Kim J, Roh M, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 2010;29(17):2477-2487.
24. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science. 1992; 257(5074):1261-1264.
25. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010; 95(6):1004-1015.
26. Ma J, Arnold HK, Lilly M, Sears R, Kraft A. Negative regulation of Pim-1 protein kinase levels by the B56[beta] subunit of PP2A. Oncogene. 2007; 26(35):5145-5153. (Pubitemid 47206954)
27. White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood. 2005; 106(7):2520-2526. (Pubitemid 41510828)
28. Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24): 2251-2259.
29. Yong ASM, Melo JV. The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22(2):181-190.
30. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010-4022. (Pubitemid 38685338)
31. Prochownik EV Li Y. The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle. 2007;6(9):1024-1029.
32. Blick M, Romero P, Talpaz M, et al. Molecular characteristics of chronic myelogenous leukemia in blast crisis. Cancer Genet Cytogenet. 1987; 27(2):349-356. (Pubitemid 17103815)
33. McCarthy DM, Rassool FV, Goldman JM, Graham SV, Birnie GD. Genomic alterations involving the c-myc proto-oncogene locus during the evolution of a case of chronic granulocytic leukaemia. Lancet. 1984;2(8416):1362-1365. (Pubitemid 15175083)
34. Oudat R, Khan Z, Glassman AB. Detection of trisomy 8 in Philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement. Ann Clin Lab Sci. 2001;31(1):68-74. (Pubitemid 32097213)